HOTAIR expression was associated with clinical tumor stage in all cancer types assessed in our meta-analysis including estrogen-dependent carcinomas (OR = 4.65, 95% CI = 2.69–8.05, P < .001), digestive system carcinomas (OR = 3.65, 95% CI = 2.49–5.34, P < .001), respiratory system carcinomas (OR = 2.92, 95% CI = 1.60–5.30, P < .001), OSCCs (OR = 4.55, 95% CI = 2.12–9.80, P < .001), and other carcinomas (OR = 6.00, 95% CI = 1.69–21.26, P = .006). This evidence concerns the gene HOTAIR and carcinoma.